Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study-Reference-Cited by-同舟云学术

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Published:2022-11 Issue:11 Volume:23 Page:1430-1440
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wainberg Zev A,Enzinger Peter C,Kang Yoon-Koo,Qin Shukui,Yamaguchi Kensei,Kim In-Ho,Saeed Anwaar,Oh Sang Cheul,Li Jin,Turk Haci Mehmet,Teixeira Alexandra,Borg Christophe,Hitre Erika,Udrea Adrian A,Cardellino Giovanni Gerardo,Sanchez Raquel Guardeño,Collins Helen,Mitra Siddhartha,Yang Yingsi,Catenacci Daniel V T,Lee Keun-Wook

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS;Muro;Ann Oncol,2019

4. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021

5. Immunotherapy in gastric cancer;Högner;Curr Oncol,2022

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach;Modern Pathology;2024-11

2. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

3. Protein isoform-centric therapeutics: expanding targets and increasing specificity;Nature Reviews Drug Discovery;2024-09-04

4. Molecular testing of gastrointestinal tumours;Diagnostic Histopathology;2024-09

5. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09